$500 Million is the total value of Logos Global Management LP's 46 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -53,034 | -100.0% | -0.44% | – |
| SVRA | Exit | SAVARA INC | $0 | – | -613,999 | -100.0% | -0.45% | – |
| NERV | Exit | MINERVA NEUROSCIENCES INC | $0 | – | -309,745 | -100.0% | -0.71% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -69,591 | -100.0% | -0.76% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -33,300 | -100.0% | -0.97% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -1,111,867 | -100.0% | -1.02% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -46,399 | -100.0% | -1.36% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -276,635 | -100.0% | -1.42% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -995,600 | -100.0% | -1.53% | – | |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -446,882 | -100.0% | -1.57% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -193,144 | -100.0% | -1.63% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -39,644 | -100.0% | -1.64% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -75,000 | -100.0% | -1.67% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -105,512 | -100.0% | -1.70% | – |
| TXG | Exit | 10X GENOMICS INC | $0 | – | -72,831 | -100.0% | -1.73% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -69,658 | -100.0% | -1.91% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -2,325,582 | -100.0% | -2.10% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -438,831 | -100.0% | -2.22% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -247,248 | -100.0% | -2.82% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -33,237 | -100.0% | -3.01% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -304,417 | -100.0% | -4.11% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -194,500 | -100.0% | -4.12% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -120,000 | -100.0% | -5.14% | – |
| MRNA | Exit | MODERNA INC | $0 | – | -460,000 | -100.0% | -5.24% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -300,000 | -100.0% | -5.35% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -187,350 | -100.0% | -6.97% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -265,600 | -100.0% | -7.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.